MedDataX Logo

Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome

NCT ID: NCT04829526

Last Updated: 2024-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this retrospective observational single-center cohort study is to gain a deeper understanding regarding the frequency, the clinical and electrophysiologic characteristics (e.g., the diagnostic work up), complications, treatment regimes, and their associations with specific courses of disease and outcomes in adult patients with the suspected or proven diagnosis of GBS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Guillain Barré Syndrome (GBS) is a rare and life-threatening neurological emergency. The aim of this retrospective study including adult GBS patients from the last 15 years treated at the University Hospital of Basel is to assess data regarding diagnostic workup, treatment, clinical course including complications and outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Guillain-Barre Syndrome (GBS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

data collection

Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* suspected diagnosis of GBS, who have been treated at the University Hospital of Basel from 01.01.2005-28.02.2021

Exclusion Criteria

* Patients with documented refusal of the general consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raoul Sutter, Prof. Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Clinic for Intensive Care Medicine, University Hospital Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinic for Intensive Care Medicine; University Hospital Basel

Basel, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Raoul Sutter, Prof. Dr. med.

Role: CONTACT

Phone: +41 61 32 87 928

Email: [email protected]

Lisa Hert, Dr. med.

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Raoul Sutter, Prof. Dr. med.

Role: primary

Lisa Hert, Dr. med.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-00402; ko21Sutter

Identifier Type: -

Identifier Source: org_study_id